Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06617481 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site contact updated
    • Eligibility criteria shortened, about 1 word
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AdventHealth
31 trials monitored
See 2 trials at risk
Prostate Cancer
2,546 trials monitored
See 172 trials at risk
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.
Trial Details
NCT Number NCT06617481
Lead Sponsor AdventHealth
Collaborators: Blue Earth Diagnostics
Conditions
(from sponsor)		 Prostate Cancer (Post Prostatectomy)
Related terms Prostatic Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov